Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393521 | 0.88 | CRBN (0.68) | CRBNDDB1TSHRNPSR1NEK2 | |
| Hydrochloric Acid SCHEMBL23067561 | 0.86 | CRBN (0.66) | CRBNDDB1TSHRNPSR1NEK2 | |
| SCHEMBL278231 | 0.78 | CRBN (0.41) | CRBNDDB1TSHRNPSR1 | |
| SCHEMBL3958832 | 0.76 | CRBN (0.40) | CRBNDDB1TSHRNPSR1 | |
| SCHEMBL3825820 | 0.76 | CRBN (0.40) | CRBNDDB1TSHRNPSR1 | |
| SCHEMBL1207857 | 0.75 | CRBN (0.47) | CRBNTSHR | |
| SCHEMBL29680626 | 0.75 | CRBN (0.42) | CRBNTSHR | |
| SCHEMBL25049547 | 0.75 | CRBN (0.42) | CRBNTSHR | |
| SCHEMBL29346409 | 0.74 | CRBN (0.79) | CRBN | |
| SCHEMBL785575 | 0.74 | CRBN (0.55) | CRBNDDB1TSHRNPSR1NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4472980-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118660880-A | Quinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023150284-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-03-22 | — | — | US | disclosed |
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | KRAS, NRAS, HRAS | CRBN 1401/4885DDB1 2280/4885TSHR 3337/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CRBN 1529/4885DDB1 809/4885TSHR 3021/4885 |
| US-20120071459-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | CRBN 3371/4885DDB1 3824/4885TSHR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.